Trials explorer

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients is being studied. Conditions: Non Small Cell Lung Cancer NSCLC • Eligibility: Inclusion Criteria: * Pathologically or histologically confirmed non-small cell lung cancer (NSCLC) * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 *…. Goal: The goal of this observational study is to learn about the relationship between TCM body constitution patterns (called "syndromes") and the effectiveness of EGFR-TKI targeted drugs in patients with lung cancer. Approximately 3000 patients with EGFR-mutant non-small cell lung cancer who are about to start or are already taking EGFR-TKI drugs as part of their regular medical care will be invited to join. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Guangzhou University of Traditional Chinese Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer is being studied. Conditions: Non-Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R…. Goal: Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan compared to standard of care (SOC). Phase/Status/Sponsor: Unknown phase; RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Advanced Cancer, Renal Cancer +15 • Eligibility: Major Inclusion Criteria: 1. Men and women 18 years of age or older. 2. 9 cohorts will be enrolled: * Cohort A1 / Exon 14 NSCLC MET inhibitor…. Goal: To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I) Phase/Status/Sponsor: Unknown phase; RECRUITING; Apollomics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC is being studied. Conditions: Non-Small Cell Lung Cancer With EGFR Mutation • Eligibility: Inclusion Criteria: * Both sexes * ≥ 18 years old * Pathologically confirmed diagnosis of NSCLC * Stage IIIB - IV by the American Joint Committee of Cancer…. Goal: This open-label randomized clinical trial aims to evaluate the glutamine plus Lactobacillus reuteri supplementation effect in a standard-of-care diet in EGFR mutant patients with advanced non-small cell lung cancer (NSCLC) under tyrosine kinase inhibitors (TKIs) therapy. The main question it aims to answer is ¿What is the effect of glutamine plus L. Phase/Status/Sponsor: Unknown phase; RECRUITING; Instituto Nacional de Cancerologia de Mexico.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

INHERIT EGFR - Studying Germline EGFR Mutations is being studied. Conditions: Lung Cancer • Eligibility: Inclusion Criteria: To participate in this study a subject must meet the eligibility of one of the following cohorts: Cohort 1 - Cancer patients with T790M in their…. Goal: Lung cancer is a common malignancy that is associated with cigarette smoking but can also affect individuals who never smoked. It is not well understood whether there are hereditary risk factors that influence the risk of lung cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests Osimertinib plus chemotherapy as the first-line treatment for adults with EGFR mutation-positive NSCLC that is locally advanced or metastatic. - It aims to learn how well this combination works and how safe it is in real-world practice, by looking at investigator-reported progression-free survival and overall survival. - The study is sponsored by AstraZeneca and is currently active but not recruiting. - Eligible participants are adults 18+ with nonsquamous NSCLC and EGFR mutations Ex19del or L858R, at stage IIIB/IIIC or IV, who are considered appropriate for first-line Osimertinib plus chemotherapy by their physician (prior therapies allowed if meeting criteria). - Key exclusions include spinal cord compression or symptomatic brain metastases, a history of interstitial lung disease or active ILD, and other severe uncontrolled conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests EGFR-targeted CAR T cell therapy in children and young adults with relapsed or refractory non-CNS solid tumors that express EGFR. It has two arms: Arm A uses EGFR CAR T cells alone, and Arm B adds a CD19-targeting component. It is a phase I, open-label, non-randomized trial to assess safety and feasibility, determine the maximum tolerated dose, describe the toxicity, and see how long the CAR T cells persist and act against tumors. Eligible participants include those with EGFR-expressing non-CNS solid tumors that are recurrent or refractory; early enrollees are ages 15–30, with later enrollees ages 1–30. Key exclusions include active infection, other active cancers, active CNS disease, pregnancy, and GVHD or significant immunosuppression; if severe toxicity occurs, cetuximab or trastuzumab may be used to help eliminate the CAR T cells.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria: 1. Signed, written informed consent 2. Male or female age ≥ 18 years 3. Patients with glioblastoma, IDH-wildtype (as defined by WHO 2021 Classification of CNS…. Goal: This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with EGFR-amplified glioblastoma, IDH-wildtype that has recurred following prior radiotherapy. This study will take place in two parts: an initial dose escalation phase followed by a dose exploration phase. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Pennsylvania.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases is being studied. Conditions: NSCLC Stage IV Without EGFR/ALK Mutation • Eligibility: Inclusion Criteria: * Patient must meet all of the following inclusion criteria to be enrolled in this study: 1. Non-small cell lung cancer diagnosed initially through pathological histology.…. Goal: It is planned to carry out a multicenter umbrella study to find the optimal organ combination and the best radioimmunotherapy combination pattern, so as to improve the survival of NSCLC patients with multiple metastases. At the same time, by using multimodal omics data, machine learning will be employed to construct a prediction model for the abscopal effect, and explore the immunoregulation of organ-specific radiotherapy and biomarkers of the abscopal effect. Phase/Status/Sponsor: Unknown phase; RECRUITING; Xinqiao Hospital of Chongqing.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer (CRC), Antineoplastic Agents, Immunological, VEGFR-TKI • Eligibility: Inclusion Criteria: * Patients aged 18 and over. * Histologically confirmed colorectal adenocarcinoma with locally advanced disease and/or unresectable metastasis(es) receiving treatment with fruquintinib under i) compassionate/early access…. Goal: The main objective of this study is to identify the prognostic factors (clinico-biological) for the efficacy (overall survival) of fruquintinib in patients with metastatic colorectal cancer. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Federation Francophone de Cancerologie Digestive.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests the drug tivozanib for biliary tract cancers (cholangiocarcinoma and gallbladder cancer) in adults who have already had chemotherapy, to find the safest and most effective dose and to learn its overall response rate. It is open-label, non-randomized, and carried out at a single center, using 28-day treatment cycles (3 weeks on, 1 week off) with efficacy checked every 8 weeks. Eligible participants are adults 18 or older with biliary tract cancer not removable by surgery who have had prior first-line chemotherapy and have adequate organ function. Key exclusions include prior tivozanib use, pregnancy, and significant cardiovascular disease or uncontrolled hypertension.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer • Eligibility: Inclusion Criteria: * Males or females aged 18 - 75 years (inclusive). * Histologically confirmed unresectable, recurrent or metastatic solid tumors. * At least one target lesion per…. Goal: HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Hansoh BioMedical R&D Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: 1. Patients must understand the requirements and content of the clinical trial and provide a handwritten signed and dated informed consent. 2. Age ≥ 18 years…. Goal: This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tang-Du Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations is being studied. Conditions: Advanced NSCLC • Eligibility: Inclusion Criteria: * Patients of either gender, aged older than 18 years. * Histologically or cytologically confirmed metastatic, or unresectable locally advanced, recurrent NSCLC. * Radiological documentation of…. Goal: This study is conducted to assess the safety, tolerability and preliminary efficacy of AST2818 in patients with advanced Non Small Cell Lung Cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; TERMINATED; Allist Pharmaceuticals, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Adult Solid Tumor, Adult Disease +5 • Eligibility: Inclusion Criteria: * Males and nonpregnant and non-breastfeeding females, aged ≥ 18 years of age at the time of signing the informed consent. * Subjects with advanced solid…. Goal: The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; TOLREMO therapeutics AG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: * Age ≥ 18 years * Willing and able to give written informed consent * Diagnosis of Glioblastoma, IDH WT as defined by the WHO 2021…. Goal: * To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Katmai Pharmaceuticals Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests whether regorafenib given as maintenance therapy after first-line treatment helps keep bone sarcoma from coming back. Participants are patients 12 years and older with confirmed primary bone sarcoma who have completed standard treatment and have no evidence of disease; they are randomized to regorafenib for up to 12 months or to placebo surveillance. The main goal is to see if regorafenib improves relapse-free survival and disease control, with results analyzed by high-risk versus low-risk relapse groups. Key exclusions include prior VEGFR inhibitors, certain cardiovascular problems, active infections, HIV, hepatitis B/C, pregnancy, and other conditions that could affect safety or adherence. The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests regorafenib plus best supportive care as maintenance therapy for high-grade bone sarcomas after standard treatment. - It is for patients aged 12 and older with confirmed high-grade bone tumors (e.g., osteosarcoma, Ewing, chondrosarcoma, UPS, leiomyosarcoma, angiosarcoma) who have evaluable residual disease that cannot be removed and did not progress after initial therapy. - Participants will receive regorafenib with BSC for up to 12 months to see if this approach can better delay progression, with progression-free rate as a key measure. - Key exclusions include prior VEGFR inhibitors, soft tissue sarcomas, certain cardiovascular problems, active infection, and pregnancy or breastfeeding.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: * Histological or pathological confirmation of metastatic pancreas adenocarcinoma. Cytological or histological evidence of metastatic disease is required. * Male or Female greater than or equal…. Goal: The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Engeneic Pty Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor is being studied. Conditions: Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma • Eligibility: * INCLUSION CRITERIA: * Participants must have histologically confirmed, low or intermediate risk prostatic adenocarcinoma verified by biopsy (NIH Laboratory of Pathology confirmation is required). * Unifocal prostate…. Goal: Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This phase II randomized trial tests whether giving a PD-1 inhibitor with chemotherapy (gemcitabine–cisplatin) followed by re-irradiation helps people with locally advanced recurrent nasopharyngeal cancer. - It compares immediate re-irradiation after chemo-immunotherapy with a strategy of selective (only certain patients) re-irradiation. - Eligible participants are adults ages 18–70 with local recurrence more than a year after initial treatment, not a candidate for surgery, who achieved complete or partial response after 4–6 cycles of chemo plus PD-1 inhibitor, and have good performance status. - Key exclusions include prior treatment for recurrent NPC or prior PD-1/PD-L1 inhibitors, active autoimmune disease requiring systemic therapy, infections such as HIV/HBV/HCV, interstitial lung disease or significant cardiovascular disease, pregnancy, or other factors that could interfere with participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests adding PDS01ADC to a liver-directed chemotherapy approach (HAIP with FUDR and dexamethasone) plus standard systemic chemotherapy for certain liver cancers. It is for adults 18 and older with unresectable cancer confined to or dominant in the liver, specifically metastatic colorectal cancer to the liver, intrahepatic cholangiocarcinoma, or adrenocortical carcinoma with liver metastases. The study aims to learn the objective response rate, i.e., how often tumors shrink, with this combination therapy. Eligible participants must have had first-line systemic chemotherapy and will receive HAIP-delivered chemotherapy, PDS01ADC injections every four weeks, and ongoing systemic chemotherapy. Exclusions include active autoimmune disease (with some steroid replacement exceptions), active hepatitis B or C infection, significant cardiovascular disease, prior FUDR exposure, and other factors that could confound results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests nanvuranlat in adults with biliary tract cancer to find a recommended dose regimen (Part A) and to study its effect on overall survival compared with the physician’s best choice (Part B). Participants are 18 years or older with advanced, metastatic, or unresectable BTC who have received one prior platinum-based therapy. Treatments are given every two weeks with safety checks, tumor imaging, and exploratory tests to understand how the drug works. Key exclusions include active CNS metastases, significant cardiovascular disease, HIV not on therapy, active HBV or HCV infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma is being studied. Conditions: T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell +5 • Eligibility: Inclusion Criteria: 1. Adult patients with T-cell lymphoma \[PTCL (all subtypes), T-PLL, ATLL, and CTCL (all subtypes)\] in partial or complete remission between day +35 and +120 from…. Goal: This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jonathan Brammer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding pembrolizumab, an immunotherapy drug, to the usual platinum-based chemotherapy after surgery helps people with certain stages of non-small cell lung cancer live longer without the cancer returning. - It is for adults who have had complete surgical removal of stage IIA-IIIB NSCLC (T3-4N2) and who have not received prior systemic treatment for this cancer. - The study compares two timing strategies: pembrolizumab after chemotherapy versus pembrolizumab given at the same time as chemotherapy, to see which approach improves disease-free and overall survival and how it affects side effects and quality of life. - Key eligibility notes include no active autoimmune disease requiring systemic therapy in the past 2 years, no active infection or pneumonitis, not pregnant, and adequate organ function; people with controlled HIV may participate under certain conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests BOLD-100 given with the chemotherapy FOLFOX in adults with advanced gastrointestinal cancers (such as colorectal, pancreatic, gastric cancers, and cholangiocarcinoma) to assess safety and tolerability, using a dose-escalation phase followed by expansion. - In the colorectal cancer arm (Arm VII), eligible patients who are oxaliplatin-naïve and have had only one prior metastatic therapy will be randomized to three groups: BOLD-100 at 500 mg/m2 with FOLFOX, BOLD-100 at 625 mg/m2 with FOLFOX, or FOLFOX alone, with quality-of-life assessments. - The trial aims to learn whether adding BOLD-100 provides anti-tumor activity and how it affects patients’ quality of life, while establishing safe dose levels. - Key exclusions include neuropathy greater than grade 2, CNS metastases, active HIV on ART, DPD deficiency, prior exposure to BOLD-100 (for Arm VII), MSI-H tumors, and recent major treatments or other serious conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a first-in-human study of VVD-159642, a RAS-PI3Kα inhibitor, in adults with advanced solid tumors. It aims to evaluate safety and tolerability, plus how the drug behaves in the body (PK/PD), and to see any early anti-tumor activity, both by itself and in combination with sotorasib or trametinib. Eligible participants include people with pancreatic ductal adenocarcinoma, colorectal cancer, non-small cell lung cancer, or any solid tumor with RAS alterations (KRAS, NRAS, HRAS), or with EGFR alterations or HER2 overexpression. Key exclusions include active CNS cancers, significant cardiac disease, uncontrolled hypertension, inflammatory bowel disease or malabsorption issues, and active hepatitis B or C infections.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations is being studied. Conditions: Non Small Cell Lung Carcinoma • Eligibility: Inclusion Criteria: * Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study. *…. Goal: Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Phase/Status/Sponsor: Unknown phase; RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial is being studied. Conditions: Glioblastoma, Recurrence Tumor • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed glioblastoma, according to World Health Organization \[WHO\] 2021 with unequivocal first progression after standard (6 weeks radiotherapy \[RT\]) with concurrent \&…. Goal: This is a multicentric phase II open-label clinical trial aiming to assess the efficacy of the combination of trimipramine and atezolizumab with bevacizumab in patients with recurrent glioblastoma. Eligible patients will be assigned to two cohorts depending on whether there is a medical indication for a neurosurgical resection from first recurrent tumor or not. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centre Hospitalier Universitaire Vaudois.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests DISC-0974 in adults with myelofibrosis or myelodysplastic syndrome who also have anemia. - It is a phase 1b/2a open-label trial aimed at safety, tolerability, pharmacokinetics, pharmacodynamics, and to categorize anemia response. - There are MF participants (with various risk levels) and an exploratory cohort of participants with MDS and anemia. - Key exclusions include active infections (HBV/HCV or HIV with detectable viral load), recent hematopoietic stem cell transplant or related immunosuppression, recent iron chelation therapy, pregnancy, and significant heart disease. - The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies is being studied. Conditions: Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma +1 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years 2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 3. Histologically confirmed diagnosis of any of the following: • Gastric or…. Goal: The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anwaar Saeed.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers is being studied. Conditions: Cancer • Eligibility: Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\] 2. Age 18 years or older, is willing and able to provide…. Goal: TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tizona Therapeutics, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer is being studied. Conditions: Non-small Cell Lung Cancer Metastatic • Eligibility: Inclusion Criteria: * Newly diagnosed, histologically verified, Non-Small Cell Lung Cancer (NSCLC) * Advanced or locally advanced disease without curative intended treatment options * Age \> 18 years…. Goal: The study is a prospective randomized interventional study including patients with advanced non-small cell lung cancer, receiving immunotherapy, with the aim of optimizing treatment monitoring. The study aims to investigate the clinical utility of liquid biopsy monitoring in order to reduce the numbers of inefficient treatments and needless toxicity - and to explore the cost-effectiveness and cost-utility of introducing liquid biopsy monitoring in daily clinical practice. Phase/Status/Sponsor: Unknown phase; RECRUITING; Zealand University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers is being studied. Conditions: Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer +1 • Eligibility: Inclusion Criteria: 1. Patients must have signed a written informed consent form prior to any trial specific procedures; 2. Patients must be ≥18 years old; 3. Histologically confirmed…. Goal: International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different tumor types. Phase/Status/Sponsor: Unknown phase; RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a three‑drug combo—Apatinib, Adebrelimab, and GEMOX chemotherapy—for adults with unresectable intrahepatic cholangiocarcinoma (ICC). It aims to see if this regimen can achieve more tumor shrinkage and longer survival, while keeping an eye on safety, compared with historical data for chemotherapy alone. Eligible participants are adults 18–75 with confirmed ICC that cannot be removed by surgery or has progressed after prior treatment, and who have good liver function and performance status. Up to 38 people will be enrolled at multiple hospitals; key exclusions include prior immune checkpoint inhibitor treatment, having another active cancer, and conditions like significant ascites or uncontrolled medical issues.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers is being studied. Conditions: Head and Neck Tumors, Kidney Cancers, Small Cell Lung Cancers +3 • Eligibility: * INCLUSION CRITERIA: * Participants must have histopathologically confirmed gastrointestinal neuroendocrine tumors (GI NET), pheochromocytoma/paraganglioma (PPGL), small cell lung cancers (SCLC), kidney cancers (KC), or Head \& Neck…. Goal: Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests adding lenvatinib to nivolumab plus chemotherapy for gastric cancer with peritoneal metastasis and malignant ascites. - It is for adults with newly diagnosed or recurrent/metastatic gastric or GEJ adenocarcinoma who have peritoneal metastasis with grade ≥2 ascites and a PD-L1 CPS ≥5. - The study aims to learn about the safety and efficacy of this combination and whether it can improve outcomes, such as survival, in this group. - Key exclusions include uncontrolled illness or infection, pregnancy or breastfeeding, HIV or active hepatitis B/C infection, recent major surgery, and other concurrent cancer therapies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer, Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma +1 • Eligibility: Inclusion Criteria: * Histological or cytological proof of pancreatic adenocarcinoma. Must have metastatic pancreatic cancer who have received at least first line chemotherapy. Disease stability or progression during…. Goal: The purpose of this study is to find the safest dose and identify any bad side effects of EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic cancer who have already received first-line standard chemotherapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests amivantamab plus FOLFIRI versus cetuximab/bevacizumab plus FOLFIRI in people with KRAS/NRAS and BRAF wild-type colorectal cancer who have previously received chemotherapy. - It aims to learn whether the amivantamab combination improves progression-free survival and overall survival compared with the cetuximab/bevacizumab combination. - Eligible participants have recurrent, unresectable, or metastatic colorectal cancer with confirmed KRAS/NRAS and BRAF wild-type status, have had at least one prior systemic therapy for metastatic disease, and have ECOG 0–1. - Key exclusions include preexisting interstitial lung disease/pneumonitis, allergies to study drugs, prior exposure to irinotecan or EGFR/MET inhibitors, HER2-positive tumors, or another active malignancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: 1. Newly-diagnosed, histologically proven, intracranial glioblastoma with maximal safe resection. Biopsy alone is expected if resection is not possible. MGMT promoter methylation status must be tested…. Goal: Currently, the optimal treatment regimen for elderly Glioblastoma (GBM) patients with poor performance status (PS) is unknown. Based on data for elderly GBM patients and the limited data for patients with poor PS, hypofractionated RT or a short course of Temozolomide (TMZ) may provide survival benefit without the added toxicity and inconvenience of a more protracted treatment regimen. Phase/Status/Sponsor: Unknown phase; RECRUITING; AHS Cancer Control Alberta.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma is being studied. Conditions: Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma +1 • Eligibility: Inclusion Criteria: Cohort 1: Must have a confirmed diagnosis of metastatic Uveal Melanoma. * Patients will be eligible regardless of the number of prior systemic therapies received. *…. Goal: This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a combo of AMXT 1501 and DFMO (eflornithine) in children and young adults up to age 21 with relapsed or refractory neuroblastoma, certain brain tumors (including DIPG), and some sarcomas. - The main goals are to find a safe, recommended dose of AMXT 1501 with DFMO, assess safety and tolerability, and learn whether the treatment shows activity by looking at responses and how long the disease stays under control. - The trial includes different age groups (adolescents and young adults 12 and older, and younger children under 12) with age-specific dose considerations. - Key exclusions include body surface area under 0.25 m2, current use of other investigational or anticancer drugs, active infection, or risk factors that would make safety monitoring unreliable.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features. is being studied. Conditions: Brain Tumor • Eligibility: Inclusion Criteria: * Patient, male or female, aged 18 years or over * Imaging suggestive of glioblastoma * Patient eligible for excision surgery (partial, subtotal or macroscopically complete)…. Goal: Glioblastoma is the most frequent and aggressive primary brain tumor in adults. A team recently showed that baseline plasma levels of matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) were correlated to bevacizumab activity in patients with recurrent glioblastoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Assistance Publique Hopitaux De Marseille.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether camrelizumab (SHR-1210) plus apatinib can extend overall survival in people with advanced gastric or gastroesophageal junction adenocarcinoma whose disease progressed after first-line platinum-based therapy. It targets adults with metastatic or unresectable disease and PD-L1–positive tumors, who have good performance status and adequate organ function. The trial aims to learn if the combination is more effective and safe, and will collect PD-L1 biomarker data from tumor tissue. Key exclusions include active CNS metastases or autoimmune disease, uncontrolled cardiovascular issues, recent major GI bleeding or thrombosis, prior anti-PD-1/PD-L1 or VEGFR inhibitor therapy, and recent systemic therapy or unresolved adverse events.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether the molecular results from a fine needle biopsy (FNB) using Thyroid GuidePx® are the same as results from the larger surgical tissue in people with papillary thyroid cancer. It is for adults with a preoperative diagnosis of papillary thyroid cancer (Bethesda V/VI) or indeterminate nodules (Bethesda III/IV) who are candidates for thyroidectomy. During surgery, an FNB of the dominant tumor will be taken and both the FNB and surgical samples will undergo RNASeq to see if the FNB can reliably classify the cancer. The goal is to find out if the smaller biopsy is sufficiently representative to guide treatment decisions before surgery. Exclusions include history of neck radiation, inability or unwillingness to have a fine needle biopsy or thyroidectomy, final pathology not showing papillary thyroid cancer, or situations with no clear dominant nodule or multiple nodules precluding sampling.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors is being studied. Conditions: Cervical Cancer, Breast Cancer, Colon Cancer +4 • Eligibility: 1. Adult participants (age ≥ 18 years old) with any of the following advanced or metastatic solid tumors (documented history of histologically confirmed diagnosis): 1. Metastatic castration-resistant prostate…. Goal: A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Orano Med LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma is being studied. Conditions: Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma +2 • Eligibility: Inclusion Criteria: * COHORT A and COHORT B: For the dose escalation phase, patients must be ≥ 12 months and \< 18 years of age at the time…. Goal: This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or diffuse intrinsic pontine glioma. AZD1390 is in a class of medications called kinase inhibitors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Children's Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: * 1\. Voluntarily participate in the study, communicate well with investigators, understand and voluntarily complete the study process according to this protocol, and sign the informed…. Goal: Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%) Phase/Status/Sponsor: Unknown phase; RECRUITING; HC Biopharma Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia is being studied. Conditions: Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia • Eligibility: Inclusion Criteria: * Documented informed consent of the participant * Agreement to allow the use of archival tissue from diagnostic tumor biopsies. * If unavailable, exceptions may be…. Goal: This phase Ib trial tests the safety, side effects, and effectiveness of humanized (hu)CD19-chimeric antigen receptor (CAR) T cell therapy in treating patients with CD19 positive B-cell acute lymphoblastic leukemia (ALL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). CAR T-cell therapy is a treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests MT-401-OTS, a cellular therapy, in adults with relapsed AML or high/very-high-risk MDS to evaluate safety and potential efficacy at escalating doses. It enrolls two groups of participants aged 65 and older: those with intermediate/high-risk AML with MRD or low blasts after prior therapy, and those with high/very-high-risk MDS with residual disease after HMA therapy. It is a Phase 1, open-label, multicenter dose-escalation study (3+3 design) to find a safe dose and gather early efficacy data, with an optional Cohort 4 for alternative dosing. Key exclusions include active CNS leukemia, active infections (e.g., HIV or hepatitis B/C), prior stem cell transplant, other active cancers (with limited exceptions), significant cardiac disease, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer is being studied. Conditions: Previously Treated Non-Small Cell Lung Cancer • Eligibility: 5.1 Registration Step 0: 1. Patients who need the fresh biopsy must also submit whole blood for ctDNA testing (see Section 15.3). These patients must be registered to…. Goal: This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; SWOG Cancer Research Network.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors is being studied. Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma +8 • Eligibility: Inclusion Criteria: 1. Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures. 2. Subjects ≥ 18 years of age at the time of signing…. Goal: Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Arizona.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC is being studied. Conditions: Metastatic Colorectal Cancer (mCRC) • Eligibility: Inclusion Criteria: 1. Male or female subjects age ≥ 18 years with a history of treated colorectal cancer with unresectable metastases of the primary colorectal cancer to other…. Goal: This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and tipiracil + bevacizumab in patients with CCR5+, MSS, mCRC who have progressed on prior treatment before participating in the study. The main questions this study aims to answer are: 1. Phase/Status/Sponsor: Unknown phase; RECRUITING; CytoDyn, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a first-in-human, multicenter, open-label Phase 1 trial testing CID-078, an oral Cyclin A/B-RxL inhibitor, for safety, tolerability, and early signs of anti-tumor activity in adults with advanced solid tumors. The study aims to identify a recommended dose for expansion and to compare safety and pharmacokinetics between the original and a new CID-078 formulation, including a test of the effect of food on its absorption. In the dose-expansion part, CID-078 will be studied for anti-tumor activity in three groups: triple-negative breast cancer, small cell lung cancer, and RB1-altered solid tumors, with a possible extra cohort expansion based on the data. Eligible participants include adults with progressed or refractory solid tumors and, in the expansion part, some adolescents aged 12 and older; key exclusions include prior CID-078 exposure, active brain metastases unless treated and stable, interstitial lung disease, significant QT prolongation risk, and certain viral infections or uncontrolled illnesses.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer +1 • Eligibility: Inclusion Criteria Patients who meet ALL the following inclusion criteria will be eligible to participate in the study: 1. ≥18 years of age. 2. Histologically confirmed, locally advanced,…. Goal: The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work. Phase/Status/Sponsor: Unknown phase; RECRUITING; JiaRay Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests APG-115, an oral mdm2 inhibitor, in people with BAP1 Cancer Syndrome who also have early-stage mesothelioma. - It is for adults 18 and older who have a germline BAP1 mutation and subclinical/early-stage mesothelioma that does not yet require standard treatment. - The trial aims to determine whether APG-115 can stabilize or improve the disease, using pre- and post-treatment biopsies and imaging to assess response, with treatment given in 21-day cycles for up to 16 cycles. - The study is not yet recruiting. - Exclusions include cancers requiring frontline therapy, significant cardiovascular disease, certain drug interactions, active viral infections (HBV/HCV/HIV), pregnancy, and other unstable medical conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases is being studied. Conditions: Glioblastoma (GBM), Brain Metastasases • Eligibility: Inclusion Criteria: * 1\. Diagnosed with: (a) GBM according to the 2021 WHO criteria, who have progressed on or following standard of care therapy, including maximal safe resection…. Goal: This will be an open-label Phase 0/1 study that will enroll approximately 15 participants, 9 participants with recurrent WHO Grade 4 glioma (rGBM) and 6 participants with brain metastases, who will receive the investigational drug risvutatug rezetecan (GSK5764227), a B7-H3-targeted antibody-drug conjugate (ADC) with the GSK5757810 payload. The trial will consist of a Phase 0 component (subdivided into Arms A and B) and an Expansion Phase 1 component. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Nader Sanai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. is being studied. Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion Criteria: * Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor. ECOG PS 0 or 1 * Presence of at least 1 measurable…. Goal: The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. Phase/Status/Sponsor: Unknown phase; RECRUITING; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors is being studied. Conditions: Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia +6 • Eligibility: Inclusion Criteria: Histologically or cytologically confirmed diagnosis of the following malignancies: \- Phase 1: CP-CML, BP-CML, AP-CML ALL. AML. Other leukemias. Lymphoma. Any other tumors, including tumors of…. Goal: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias, lymphomas, and solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Incyte Biosciences International Sàrl.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests whether adding luspatercept to best supportive care can reduce the need for regular red blood cell transfusions in adults with anemia due to lower-risk MDS or non-proliferative MDS/MPN neoplasms. - It also aims to learn about the safety and tolerability of luspatercept in these patients. - Eligible participants are adults (18 or older) with MDS or non-proliferative MDS/MPN, certain splicing gene mutations, low marrow blasts, and who are refractory, intolerant to, or ineligible for prior ESA therapy and transfusion-dependent (average ≥2 units of RBCs every 8 weeks for at least 16 weeks). - The study excludes people who have had a stem cell transplant, certain del(5q) MDS without lenalidomide, uncontrolled hypertension, very low blood counts, active other cancers, or severe kidney or liver problems, as well as those who have had prior luspatercept or sotatercept, or who are pregnant. - Overall, researchers want to know if luspatercept can lessen transfusion needs while monitoring its safety in this specific MDS/MPN population.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases is being studied. Conditions: Brain Metastases, Tumor • Eligibility: Inclusion Criteria: Patients are eligible to be included in the study only if all the following criteria apply: 1. Male/female patients who are at least 18 years of…. Goal: This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases. The study will be comprised of 3 patient cohorts: triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and solid tumor types other than TNBC and NSCLC. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors is being studied. Conditions: Solid Tumor • Eligibility: Inclusion Criteria: 1. Must be ≥ 18 years of age when signing informed consent. 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 without deterioration in…. Goal: This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody，LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; L & L Bio Co., Ltd., Ningbo, China.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study is being studied. Conditions: Diabetes, Prostate Cancer • Eligibility: Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate that is localized (no metastatic lesions or concerning lymph nodes 1cm or greater) based on prostate MRI and meets…. Goal: The goal of this clinical research study is to determine how well a tirzepatide-assisted weight loss program works before a prostatectomy in patients with intermediate risk prostate cancer Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC) is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Agrees to follow the trial protocol and visit schedule, has signed informed consent; 2. Subjects must be ≥18 years of age at time of informed…. Goal: This is a first-in-human, single-arm, open-label, dose escalation prospective phase I clinical study to evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Alone in patients with Unresectable, Metastatic or Advanced pancreatic cancer or Non-small Cell Lung Cancer(NSCLC) after Standard Treatment Failure. The primary objective is to evaluate the safety and tolerability of TMT101 Injection as monotherapy in patients with advanced pancreatic cancer and NSCLC, and to determine the recommended therapeutic dose (RD) of TMT101 Injection as monotherapy Phase/Status/Sponsor: Unknown phase; RECRUITING; Peking Union Medical College Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether inhaled nitric oxide given during cardiac surgery that uses a heart-lung machine (cardiopulmonary bypass, CPB) can reduce the risk of death and major complications within 30 days after surgery. It is for adults 18 and older undergoing elective cardiac or aortic surgery that requires CPB. The study aims to learn if inhaled nitric oxide lowers the need for intensive life support and improves outcomes such as kidney injury, respiratory failure, heart attack, stroke, and sepsis. Exclusions include emergency surgery, surgery needing deep hypothermic circulatory arrest, planned congenital heart disease repair, or heart transplantation, and also severe preexisting heart failure on support, prior inhaled NO or prostacyclin therapy, end-stage kidney disease, bleeding disorders, or terminal illness with life expectancy under 1 year.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests accelerator-based boron neutron capture therapy (BNCT) for locally recurrent head and neck cancer using the nuBeam Suite and L-BPA fructose. - It is for adults with histologically confirmed, inoperable head and neck carcinoma that has recurred after prior radiation (chemoradiation may have been given). - The trial aims to learn whether BNCT can be delivered safely and as planned, and to gather data on tumor response, progression-free and overall survival, and quality of life. - It is a small, non-randomized, single-center Phase I study with up to 10 patients to assess safety; key exclusions include distant metastases, poor performance status, recent major surgery, concurrent uncontrolled cancer or therapies, pregnancy, and certain implants or health conditions that could affect treatment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 is being studied. Conditions: Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma +11 • Eligibility: Inclusion Criteria: * Frozen biopsy consistent with glioma by neuropathologist at the time of the first surgery in this longitudinal trial. Biopsy confirmation of glioma or infiltrative glioma…. Goal: This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Trial of BMS-986504 in Recurrent GBM Patients is being studied. Conditions: Glioblastoma WHO Grade IV • Eligibility: Inclusion Criteria: * Participants with the diagnosis of glioblastoma by the 2021 WHO criteria, who have progressed on or following previous tumor-directed therapy, which must have included a…. Goal: This is an open-label, multi-center, Phase 0/1 dose-escalation trial designed to enroll up to 9 total recurrent glioblastoma (rGBM) participants with confirmed MTAP loss/deletion in their archival or pretreatment biopsy tissue, who are scheduled for surgical resection. MTAP loss/deletion will be determined by next-generation sequencing (NGS). Phase/Status/Sponsor: Unknown phase; RECRUITING; Nader Sanai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether a program of physical activity plus a healthy diet can improve muscle health and metabolism in women with endometrial cancer who are planned for staging surgery. - It compares women who follow the exercise and diet plan to a group that does not exercise, measuring muscle size, strength, and function, along with blood markers related to muscle health, inflammation, and glucose/lipid metabolism. - The researchers want to see if these changes are linked to better surgical recovery and overall health, and whether blood tests could help monitor muscle health. - Eligible participants are women 18–65 with endometrioid endometrial cancer who are candidates for staging surgery and able to attend sessions; key exclusions include advanced disease, another cancer, uncontrolled hypertension, kidney dysfunction, and other conditions that make exercise unsafe.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This clinical trial is testing intravenous HNF4α srRNA in adults with locally unresectable or metastatic colorectal cancer to evaluate safety and tolerability and to gather early clues about its effectiveness. - It is a single-arm, open-label, first-in-human dose-escalation study with three dose levels (25 μg, 50 μg, 100 μg) given initially, with a second treatment about 14 ± 3 days later and subsequent cycles roughly every 28 ± 7 days; the investigators may add immunotherapy after review of safety and prior results. - Eligible participants include adults with histologically confirmed CRC that cannot be removed surgically or has metastasized and who have progressed on or cannot tolerate standard therapies, including those with dMMR/MSI-H tumors and measurable disease. - Key exclusions noted are brain metastases, significant liver or kidney dysfunction, uncontrolled infections or autoimmune disease, recent cancer treatments, pregnancy or lactation, and infection with HIV or active HBV/HCV.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests whether adding preoperative [18F]F-FAPI PET-CT can better detect metastases and change treatment plans for adults with proximal cholangiocarcinoma that may be surgically removable. It is for adults 18 and older with potentially curable proximal cholangiocarcinoma who are planned for surgery based on CT and MRI imaging. The study will measure diagnostic accuracy and cost-effectiveness of FAPI PET-CT, with about six months of follow-up and questionnaires on quality of life and healthcare use. Exclusions include prior abdominal surgery or chemotherapy, pregnancy or lactation, a need for FDG PET-CT, and inability to lie still for PET-CT; the study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients is being studied. Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer • Eligibility: Inclusion: 1. Age ≥18 years on day of signing informed consent. 2. Specific by tumor cohorts: a. For the HSNCC cohort, histologically confirmed diagnosis of advanced and/or metastatic…. Goal: This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Vyriad, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer is being studied. Conditions: Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion criteria: * Participant must have histologically or cytologically confirmed metastatic NSCLC characterized by a KRAS G12C mutation at the time of enrollment. For Phase 1: Participant must…. Goal: The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose \[RP2CD\]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents the growth of tumors in participants with KRAS G12C mutant metastatic non-small cell lung cancer (NSCLC: the most common type of lung cancer; metastatic: has spread to other parts of the body; KRAS G12C mutant: mutation \[change\] in the kirsten rat sarcoma viral oncogene homolog \[KRAS\] gene in tumor cells in which glycine \[G\] at position 12 is replaced with cystine \[C\]). Phase/Status/Sponsor: Unknown phase; RECRUITING; Janssen Research & Development, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy is being studied. Conditions: Lymphedema, Breast Cancer, Lymphedema • Eligibility: Inclusion Criteria: * Ages 18 to 75 years (inclusive) * Patients undergoing unilateral or bilateral breast cancer related axillary lymphadenectomy * Free of distant metastasis in preoperative screening…. Goal: Lymphedema is a chronic, progressive, and debilitating condition that occurs with disruption or obstruction of the lymphatic system, which commonly occurs a result of breast cancer therapy. The purpose of this study is to determine if the use of a low risk lymphatic reconstruction procedure at the time of axillary lymph node dissection will reduce the risk of developing lymphedema. Phase/Status/Sponsor: Unknown phase; RECRUITING; Stanford University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a pilot phase Ib trial testing dapagliflozin, an SGLT2 inhibitor, added to standard cancer treatment for children and adolescents with recurrent brain tumors or relapsed/refractory solid tumors. The study aims to determine if dapagliflozin is safe and tolerable in this group and to see if it might help treatment when added to chemotherapy by affecting tumor markers through metabolic effects. Eligible participants are aged 6–21 with a recurrent brain tumor or relapsed/refractory solid tumor for whom no curative therapy is available. Key exclusions include current or prior SGLT2 inhibitor use, high‑dose dexamethasone, type 1 diabetes or insulin treatment, very high HbA1c, recent stroke, pregnancy, or significant kidney disease.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma is being studied. Conditions: Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma • Eligibility: Inclusion Criteria: * Histologic diagnosis of classical Hodgkin's lymphoma. Primary refractory or relapsed disease proven by biopsy at enrolling institution. * Stage I-III Hodgkin lymphoma (part 3) *…. Goal: The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Have a full understanding of the study content, process, and possible adverse reactions before the study, and sign the informed consent form (ICF); voluntarily participate…. Goal: The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Henlius Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer is being studied. Conditions: Gastric Cancer Stage IV • Eligibility: Inclusion Criteria: 1. Provided written informed consent for treatment. 2. Age ≥ 19 years old 3. measurable or evaluable disease based on RECIST 1.1. Lesions 4. Eastern Cooperative…. Goal: Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Olaparib is a potent PARP inhibitor (PARP1, 2, and 3) that is being developed as a monotherapy as well as for combination with chemotherapy, ionizing radiation, and other anti-cancer agents including novel agents and immunotherapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Yonsei University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3) is being studied. Conditions: Glioblastoma Multiforme, Adult • Eligibility: Inclusion Criteria: * Histopathologically confirmed, based on biopsy or surgical resection, glioblastoma, or grade 4 astrocytoma, as defined by the World Health Organization (WHO) * Deemed clinically appropriate…. Goal: The goal of this study is to test whether an adaptive radiation therapy (RT), two-phase approach in participants with glioblastoma impacts local control compared to standard non-adaptive RT approach. The main questions of the study are to see how this adaptive, two-phase RT approach compares to standard RT in terms of: * Local control * Overall and progression-free survival * Patterns of failure * Toxicity, Neurological Function, and Quality of Life Phase/Status/Sponsor: Unknown phase; RECRUITING; Sunnybrook Health Sciences Centre.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) is being studied. Conditions: Non-small Cell Lung Cancer (NSCLC) • Eligibility: Inclusion Criteria * Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III disease. * Participants must have received at…. Goal: A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC) Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma is being studied. Conditions: Vitamin D 25-Hydroxylase Deficiency, Lymphoma Non-Hodgkin • Eligibility: Inclusion Criteria: * Age ≥ 20 years. * Newly diagnosed aggressive non-Hodgkin lymphoma, confirmed by histopathological examination according to the WHO Classification of Haematolymphoid Tumours, 5th edition, with…. Goal: The goal of this clinical trial is to evaluate whether a high-intensity loading dose of ergocalciferol (vitamin D2) can normalize blood vitamin D levels more rapidly and safely than standard weekly dosing in patients with newly diagnosed aggressive non-Hodgkin lymphoma. The study will also assess the safety of both dosing strategies. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Phramongkutklao College of Medicine and Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Huaier Granule and Proteinuria is being studied. Conditions: Proteinuria, Breast Cancer Patients • Eligibility: Inclusion Criteria: * \*\*Inclusion Criteria\*\* 1. Female patients aged 18-75 years. 2. Histopathologically confirmed diagnosis of breast cancer. 3. Currently receiving or having a prior history of immunotherapy…. Goal: The goal of this clinical trial is to learn if adding Huaier Granule to standard care can treat proteinuria (excess protein in the urine) in adult female breast cancer patients (aged 18-75) who developed this condition as a side effect of their immunotherapy or anti-angiogenic cancer treatment. The main question it aims to answer is: \* Does the addition of Huaier Granule to standard care improve the effectiveness of proteinuria treatment after 8 weeks? Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Fudan University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

iNO300 Therapy in Critically Ill Patients With Pneumonia is being studied. Conditions: Critical Illness, Pneumonia • Eligibility: Inclusion Criteria: * 18 years or older * Intubated and mechanically ventilated * Within 72h of diagnosis of community- or hospital-acquired pneumonia * Written informed consent obtained from…. Goal: The goal of this clinical trial is to learn the formation and recovery rate of methemoglobin (MetHb) in severely sick patients with pneumonia who receive high doses of inhaled nitric oxide (iNO) therapy at 250 parts per million (ppm), not exceeding 300 ppm. Meanwhile, the benefits of the therapy to treat severely sick patients with pneumonia will be explored. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old. 2. Inclusion criteria for the study population： Phase 1: Advanced Solid tumors. Phase 2: Extensive-stage SCLC, Non-AGA NSCLC, EGFR mutation…. Goal: This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; MediLink Therapeutics (Suzhou) Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma is being studied. Conditions: Extranodal Marginal Zone Lymphoma • Eligibility: Inclusion Criteria: 1. Men and women aged 18 years or older at the time of signing informed consent. 2. Able and willing to sign the informed consent form…. Goal: The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer is in stage I-IV. Phase/Status/Sponsor: Unknown phase; RECRUITING; Izidore Lossos, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors is being studied. Conditions: Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) +6 • Eligibility: Inclusion Criteria: Part A, B, and C: * Written informed consent, dated and signed by the patient prior to any study-specific procedure. * Part B and C are…. Goal: The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of \[68Ga\]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) \[maximum tolerated dose (MTD) or lower dose\] for \[177Lu\]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of \[177Lu\]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic concordance between \[68Ga\]Ga-DPI-4452 Positron Emission Tomography (PET) and the histopathology result of the Indeterminate Renal Mass (IDRM); Part E: is to assess \[68Ga\]Ga-DPI-4452 uptake in each tumour type such as UC, muscle invasive bladder cancer (MIBC), head and neck cancer (H\&N), triple negative breast cancer (TNBC), squamous non-small cell lung cancer (NSCLC), and any other tumor with locally confirmed carbonic anhydrase (CA) IX expression except ccRCC, CRC and PDAC. Phase/Status/Sponsor: Unknown phase; RECRUITING; ITM Oncologics GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a drug called MGC028 in adults whose ADAM9-expressing solid tumors are relapsed or refractory, unresectable, locally advanced, or metastatic. - It uses dose escalation to find a safe dose and to describe safety and side effects, including any dose-limiting toxicities and the highest dose that can be given safely. - The trial also aims to learn whether MGC028 can shrink tumors, keep cancer from growing, or control disease in these advanced cancers. - Cancers eligible for participation include NSCLC adenocarcinoma, cholangiocarcinoma, colorectal cancer, and pancreatic cancer with specific prior-treatment criteria; key exclusions include active brain metastases, prior ADAM9-targeted therapy, recent major cancer treatment, organ transplant, infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors is being studied. Conditions: Solid Tumours, Sarcoma, HNSCC +9 • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed disease, locally advanced or metastatic: For Phase 1a: Solid tumor with a COX2-associated immunosuppressive pathway, for which standard treatment options are…. Goal: The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; Epkin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pilot Trial for Treatment of Recurrent Glioblastoma is being studied. Conditions: Glioblastoma, Recurrent Disease, Recurrent Glioblastoma • Eligibility: Inclusion Criteria: 1. Study participant has provided informed consent prior to initiation of any study specific activities/procedures. 2. Adult participants, male and female, aged ≥18 who have a…. Goal: This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their recurrent GBM tumor resected at the time of surgery. It will be aimed to gather preliminary information on the study intervention and the feasibility of conducting a full-scale trial. Phase/Status/Sponsor: Unknown phase; RECRUITING; AHS Cancer Control Alberta.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) is being studied. Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7 • Eligibility: Inclusion Criteria: * Age \>= 18 years * Patients must have undergone complete surgical resection of their stage IB (\>= 4 cm), II or IIIA NSCLC according to…. Goal: This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) is being studied. Conditions: mCRPC • Eligibility: Inclusion Criteria: 1. Male, aged 18 to 85 years. 2. Histologically confirmed prostate adenocarcinoma, without small cell carcinoma components. 3. Metastatic Castration-Resistant Prostate Cancer (mCRPC) with disease progression…. Goal: This open-label, single-arm study evaluates the safety and preliminary efficacy of LC-K76 combined with Tislelizumab and ADT in 10 patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who progressed on prior therapies. Participants will receive oral LC-K76 and intravenous Tislelizumab for a 24-week treatment period. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Changzheng Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer is being studied. Conditions: Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 +2 • Eligibility: Inclusion Criteria: * PRE-REGISTRATION (STEP 0) ELIGIBILITY CRITERIA: * BRAF V600 mutational status may be determined either locally or by central testing. This testing is mandatory prior to…. Goal: This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Alliance for Clinical Trials in Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

First in Human Study of QLS5316 in Solid Tumors is being studied. Conditions: Solid Tumors, Colorectal Cancer, Gastric Cancer or Gastroesophageal Junction Adenocarcinoma +2 • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years 2. Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1 3. Life expectancy ≥ 3 months; 4. Measurable disease per RECIST v1.1…. Goal: This is a first-in-human (FIH) Phase I, multi-center, open-label, study of QLS5316, in patients with advanced solid tumors. The study aim to evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and immunogenicity of QLS5316 as monotherapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Qilu Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. voluntarily sign a written informed consent to participate in the study and be willing and able to comply with study-related visits and procedures; 2. Male…. Goal: The goal of this clinical trial is to test if PLB1001 works well and safely in Non-small cell lung cancer patients with MET exon 14 mutation. The main questions it aims to answer are: * If it is works well in Non-small cell lung cancer patients with MET exon 14 mutation * If it is safety and tolerant in Non-small cell lung cancer patients with MET exon 14 mutation Participants will 1. Phase/Status/Sponsor: Unknown phase; RECRUITING; Beijing Pearl Biotechnology Limited Liability Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH is being studied. Conditions: Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren&#39;s Syndrome Combined With Pulmonary Hypertension • Eligibility: Inclusion Criteria: * 1\. Refractory lupus nephritis (LN): Definition: A treatment regimen using at least one immunosuppressive agent (including glucocorticoids, CTX, tacrolimus, mycophenolate mofetil, and cyclosporine) that does…. Goal: This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), and primary Sjogren syndrome combined with pulmonary artery hypertension (pSS-PAH) receive CD19-BCMA CAR T cell therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Beijing GoBroad Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The INTUITT-NF2 Master Study is a basket, multi-arm Phase II trial testing two targeted drugs, brigatinib and neratinib, in people with NF2-related schwannomatosis and progressive NF2 tumors (vestibular schwannomas, non-vestibular schwannomas, meningiomas, and ependymomas). The study aims to learn whether these drugs are safe and can shrink or stabilize tumors by measuring radiographic response rates across tumor types. Eligible participants have an NF2 gene variant or meet NIH/Manchester criteria and show measurable progression of a target NF2-related tumor, and they must be at least 12 years old; key exclusions include recent chemotherapy or radiation to the target tumor, use of other investigational drugs, uncontrolled cardiovascular disease, and pregnancy—note that the brigatinib arm is currently closed to enrollment. About 80 people are planned to participate, with up to 40 per sub-study, and the study can follow participants for up to 10 years, allowing switching between sub-studies if tumors grow.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) is being studied. Conditions: Lung Cancer, Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Willing and able to provide written informed consent/assent for the trial. * Be ≥ 18 years of age on day of signing informed consent. *…. Goal: The main purpose of this study is to see whether the combination of two drugs called pembrolizumab and vorinostat can help people with advanced lung cancer. Researchers also want to find out if the combination of pembrolizumab and vorinostat is safe and tolerable. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; H. Lee Moffitt Cancer Center and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer is being studied. Conditions: Biliary Tract Cancer (BTC) • Eligibility: Inclusion Criteria: 1. Provide written informed consent prior to any study procedures and agree to adhere to all protocol requirements 2. Aged at least 18 years. 3. Has…. Goal: The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS). Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to receive either 60 mg D07001-softgel, 100 mg D07001-softgel, or placebo, combine with capecitabine. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; InnoPharmax Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC is being studied. Conditions: Non-squamous Non-small-cell Lung Cancer • Eligibility: Inclusion Criteria: * Signed Informed Consent Form (ICF) * Age ≥ 18 years at time of signing ICF * Ability to comply with the study protocol, in the…. Goal: To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Georgetown University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) is being studied. Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma +3 • Eligibility: Inclusion Criteria: * Participants must be assigned to S1900E. Assignment to S1900E is determined by the LUNGMAP protocol genomic profiling using the FoundationOne assay. Biomarker eligibility for S1900E…. Goal: This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; SWOG Cancer Research Network.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This randomized study tests whether adding ganitumab, a drug that blocks the IGF-1R pathway, to standard multiagent chemotherapy improves outcomes for newly diagnosed metastatic Ewing sarcoma. It is for patients whose cancer has spread to the lungs, bones, bone marrow, or other sites. The main goal is to see if event-free survival is better with ganitumab, and it also looks at overall survival and treatment toxicity, plus many exploratory biomarker and imaging studies to understand how the treatment works. Key exclusions include disease limited to regional lymph nodes, tumors in the brain or spinal cord, prior chemotherapy or radiation, pregnancy or contraception requirements for females of childbearing potential, diabetes, and chronic high-dose corticosteroid use.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma is being studied. Conditions: Mantle Cell Lymphoma • Eligibility: Inclusion Criteria: * Confirmed diagnosis of mantle cell lymphoma with CD20 positivity and chromosome translocation t(11;14), (q13;q32) and/or overexpress cyclin D1 in tissue biopsy * Include patients who…. Goal: This phase II trial studies how well acalabrutinib works in treating patients with mantle cell lymphoma that cannot tolerate ibrutinib. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective Evaluation of Early Acupuncture for Immediate Continence Enhancement After Prostatectomy is being studied. Conditions: Prostate Cancer, Urinary Incontinence • Eligibility: Inclusion Criteria: 1. Patients who have undergone radical prostatectomy with a confirmed pathological diagnosis of prostate cancer. 2. One week post-radical prostatectomy (RP). 3. Karnofsky Performance Score (KPS)…. Goal: This study is being done to see if early acupuncture treatment can help men control their urination better right after their urinary catheter is removed following prostate cancer surgery (radical prostatectomy). Leaking urine is a very common problem immediately after this surgery, and current treatments often start after the catheter is already out. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Bin Xu.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests a radioactive drug called 212Pb-VMT-α-NET to find a safe dose for future studies in people with neuroendocrine tumors. It is for adults with well-differentiated neuroendocrine tumors that cannot be cured with surgery and have progressed, including those who have had prior PRRT and have tumors that light up on SSTR PET scans. The study aims to learn whether the treatment is safe and tolerable, estimate the kidney radiation dose using imaging, and determine the recommended dose for future trials. The trial uses two treatments about 8-10 weeks apart, with kidney-protective amino acids and anti-nausea meds, and participants are followed for at least 6 months (with lifelong follow-up); key exclusions include pregnancy or breastfeeding, poor kidney or liver function, very low blood counts, recent cancer therapy, or a history of congestive heart failure.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Metabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS is being studied. Conditions: Polycystic Ovary Syndrome, Metformin • Eligibility: Inclusion Criteria: * • Newly diagnosed women of reproductive age (18 - 35 years) PCOS patients Exclusion Criteria: * • Patients having known similar endocrine disorders (hypothyroidism, hyperprolactinemia,…. Goal: The aim of this study is to see the associations of metabolic responses of metformin with single nucleotide polymorphisms (SNPs) (rs628031 and rs2282143) of solute carrier family 22 member 1 (SLC22A1) gene in women with polycystic ovary syndrome (PCOS). This prospective clinical study will be conducted in the department of Endocrinology, Bangabandhu Sheikh Mujib Medical University (BSMMU) from February 2023 to September 2024 over a period of two years. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer is being studied. Conditions: Non Small Cell Lung Cancer, Lung Cancer, Nsclc +2 • Eligibility: Inclusion Criteria: * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.…. Goal: The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests molecular analyses of blood, tumor tissue, normal tissue, and other body fluids to learn about cancer development, growth, and spread. - It is for adults with thoracic cancers: non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma, mesothelioma, or cancer of unknown primary presenting in the chest. - The goal is to identify markers that help diagnose cancer, predict outcomes, and predict response to targeted therapies, and to find targets for new treatments. - The project aims to create a registry of patients and tumors to better understand molecular changes in thoracic cancers and aid early detection. - Enrollment is by invitation, and participants must be able to give informed consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression is being studied. Conditions: Non-small Lung Cancer • Eligibility: Inclusion Criteria: * Age ≥ 18 years. * Histologically or cytologically metastatic NSCLC (UICC/AJCC TNM Staging System, 9th Edition, Stage Ⅳ). * At least one measurable target tumor…. Goal: This is a multicenter, non-interventional, observational real-world study to evaluate the efficacy and safety of Taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC) following Entrectinib progression. Patients deemed eligible for Taletrectinib by their physicians were enrolled after providing informed consent. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Innovent Biologics (Suzhou) Co. Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors is being studied. Conditions: Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma +23 • Eligibility: Inclusion Criteria: * Patients must have histologically confirmed, metastatic or unresectable malignancy of the following types: (a) non-small cell lung cancer (NSCLC), (b) triple-negative breast cancer (TNBC; defined…. Goal: This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer is being studied. Conditions: Colon Cancer, Colorectal Cancer • Eligibility: Inclusion Criteria: * Histologically confirmed diagnosis of adenocarcinoma of the colon or rectum with KRASG12C mutation. KRASG12C on ctDNA may also be used as basis of eligibility, with…. Goal: To find the recommended dose of MRTX849 that can be given in combination with cetuximab and irinotecan to patients with colorectal cancer that have a mutation (genetic change) called KRAS G12C. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors is being studied. Conditions: Solid Tumors • Eligibility: Inclusion Criteria: * Pathologically confirmed diagnosis of high-grade serous ovarian, primary peritoneal, or fallopian tube carcinoma * Presence of measurable recurrence, with RECIST measurable disease at the time…. Goal: The purpose of this phase I study is to test the safety of different dose levels of specially prepared cells collected called "modified T cells". In the screening part of this study the tumor was found to have a protein called MUC16. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC is being studied. Conditions: Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer • Eligibility: Inclusion Criteria: * Voluntarily signs the informed consent form. * Aged between 18 and 80 years (inclusive) at the time of consent; no gender restriction. * Histologically confirmed…. Goal: This is a single-arm, multi-center, exploratory study evaluating the efficacy and safety of iparomlimab and tuvonralimab (QL1706) in combination with bevacizumab for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic colorectal cancer. Eligible participants who meet the inclusion and exclusion criteria will provide written informed consent and receive QL1706 at 5.0 mg/kg and bevacizumab at 7.5 mg/kg on Day 1 of every 3-week cycle (Q3W), until disease progression or completion of 2 years of treatment. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Qianfoshan Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy is being studied. Conditions: Neurocognitive Impairment, Mild • Eligibility: Inclusion Criteria: * Age ≥18 years * History of COVID-19 that is confirmed by a positive polymerase-chain-reaction (PCR) test,rapid antigen test (RAT) or as per the state guidelines…. Goal: STRONGER is an international, investigator initiated and conducted, pragmatic clinical trial to determine whether 40mg atorvastatin daily can improve neurocognitive function in adults with long COVID neurological symptoms. The objective is to determine effectiveness of treatment with 40mg atorvastatin over 12 months on attenuating cognitive decline and neuroinflammatory biomarkers in adults with long COVID neurological symptoms. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; The George Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase II, open-label, single-arm study testing AK104 (Cadonilimab) as a monotherapy for adults with recurrent or metastatic high-grade neuroendocrine carcinoma of the cervix who have already received prior treatment. It aims to estimate progression-free survival at 6 months and to assess response rates, duration of response, safety, and tolerability. The study also looks at whether HPV cell-free DNA in the blood could serve as a marker of response. Key exclusions include brain metastases, active infections, HIV or hepatitis B/C infection, autoimmune disease, and recent or prior immunotherapy or other anticancer treatments.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests cabozantinib s-malate as a treatment for osteosarcoma or Ewing sarcoma that has relapsed or grown after standard therapy. - The study aims to see if cabozantinib can shrink tumors or stop their growth, with a focus on six-month responses measured by RECIST criteria. - It also looks at longer-term outcomes such as progression-free and overall survival, plus safety. - The trial is sponsored by the National Cancer Institute and is currently active but not recruiting. - Key exclusions include prior cabozantinib, recent cancer therapies, untreated brain metastases or major heart problems, pregnancy or breastfeeding, and HIV infection on antiretroviral therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer is being studied. Conditions: Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7 +3 • Eligibility: Inclusion Criteria: * Patients must have histologically or cytologically confirmed non-small cell lung cancer (cohort 1) or colorectal cancer (cohort 2) * Patients must have measurable disease, defined…. Goal: This randomized phase II trial studies the side effects of durvalumab and tremelimumab and to see how well they work with or without high or low-dose radiation therapy in treating patients with colorectal or non-small cell lung cancer that has spread to other parts of the body (metastatic). Immunotherapy with durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer is being studied. Conditions: Metastatic Colorectal Cancer • Eligibility: Inclusion Criteria: * Patients who voluntarily sign the informed consent form (ICF) and can understand and comply with the study requirements; * Males and females aged 18 to…. Goal: The purpose of this study is to evaluate the efficacy and safety of QL1706 Injection in combination with bevacizumab and XELOX compared with placebo in combination with bevacizumab and XELOX for first-line treatment in patients with unresectable mCRC. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Qilu Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sonodynamic-Chemoradiotherapy Integration in Glioblastoma is being studied. Conditions: Glioblastoma (GBM) • Eligibility: Inclusion Criteria: 1. Signed informed consent form; 2. Age \< 75 years; 3. Newly diagnosed postoperative glioblastoma patients pathologically confirmed as glioblastoma; 4. Absence of severe hematopoietic dysfunction…. Goal: This Phase II trial tests if sonodynamic therapy (SDT)-a non-invasive treatment using ultrasound to activate a cancer-killing drug-improves outcomes for newly diagnosed glioblastoma patients. Who? Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; Yingjuan Zheng.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients is being studied. Conditions: Glioblastoma • Eligibility: Inclusion Criteria Dose Escalation Cohorts: 1. Written informed consent 2. Age ≥18 years 3. Patient agreement to diagnostic and scientific work-up of glioblastoma tissue obtained during the preceding…. Goal: The purpose of this study is to obtain first, exploratory information on the safety and efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete tumor resection, and (ii) olaptesed pegol in combination with radiation therapy and bevacizumab in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete or complete tumor resection. Further arms are included (i) to establish safety for the combination of olaptesed pegol at three different doses in addition to radiotherapy and bevacizumab, (ii) to explore the benefit of combining olaptesed pegol at different dose levels with bevacizumab in order to define the doses to move forward into a subsequent randomized dose-finding study, (iii) to explore the contribution of the therapy components olaptesed pegol and bevacizumab to patient benefit and (iv) to put the clinical outcome of these treatment regimens into perspective with the standard of care treatment with temozolomide and radiotherapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; TME Pharma AG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer is being studied. Conditions: Lung Cancer, SCLC • Eligibility: Inclusion Criteria: The patients must satisfy all of the following inclusion/exclusion criteria in order to be eligible for the study: * Must have signed and dated written informed…. Goal: This is an open-label Phase I/II study, with a dose escalation part (Phase I) and a single-arm part (Phase II), in patients with recurrent SCLC who progressed after first-line platinum-based chemotherapy and who are candidates for second line therapy. No PK evaluation is planned in this study as nivolumab and ipilimumab are unlikely to alter plinabulin's PK, since the route of excretion is different. Phase/Status/Sponsor: Unknown phase; COMPLETED; Salma Sabbour.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... is being studied. Conditions: Metastatic Melanoma, Skin Cancer • Eligibility: * INCLUSION CRITERIA: 1. Measurable metastatic melanoma with at least one lesion that is resectable for tumor infiltrating lymphocytes (TIL) generation. The lesion must be of at least…. Goal: Background: \- An experimental treatment for metastatic melanoma involves cell therapy, in which researchers take white blood cells (lymphocytes) from the tumor tissue, grow them in the laboratory in large numbers, and then use the cells to attack the tumor tissue. Before receiving the cells, chemotherapy is needed to temporarily suppress the immune system to improve the chances that the tumor-fighting cells will be able to survive in the body. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy is being studied. Conditions: Metastatic Colorectal Cancer, Pancreas Adenocarcinoma, Cholangiocarcinoma • Eligibility: Inclusion Criteria: Newly referred patients with advanced pancreatic cancer (\~20/year), Cholangiocarcinoma (\~20/year), metastatic colorectal cancer (mCRC) (\~50/year) and anti-EGFR-treated mCRC patients (\~10/year) to Oslo University Hospital are eligible…. Goal: Circulating tumor DNA assays are becoming relevant for routine diagnostics, but many related aspects are yet unresolved. With this project, the investigators aim to develop pragmatic molecular diagnostic pathways of liquid biopsies relevant in advanced gastrointestinal malignancies with focus on clinical utility and sensible use of resources. Phase/Status/Sponsor: Unknown phase; TERMINATED; Oslo University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types is being studied. Conditions: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer +6 • Eligibility: Inclusion Criteria: * Subjects must have had at least one prior treatment with systemic therapy for advanced and unresectable, or metastatic disease OR is intolerant to, has refused…. Goal: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Phase/Status/Sponsor: Unknown phase; SUSPENDED; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas is being studied. Conditions: Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain +1 • Eligibility: Inclusion Criteria: * Age ≥18 years * Evidence of primary or recurrent high-grade gliomas (HGG) that in the opinion of the treating team would require surgical resection *…. Goal: This research is being done to find out if the study drug (ketoconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Ketoconazole is a drug which doctors already use for fungal infections and is thought to be able to effect tumor cells. Phase/Status/Sponsor: Unknown phase; TERMINATED; Milton S. Hershey Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer is being studied. Conditions: Extensive-Stage Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Patients who sufficiently understand this study and is willing to sign the ICF; 2. Aged from 18 to 75 years (inclusive); 3. Patients with histologically…. Goal: This is an open-label, multi-center Phase II study designed to evaluate the efficacy and safety of Surufatinib plus anti-PD-1/L1 as maintenance therapy after first-line standard of care in patients with ES-SCLC. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hutchison Medipharma Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab is being studied. Conditions: Glioblastoma, Glioblastoma Multiforme, Gliosarcoma +2 • Eligibility: * General Inclusion Criteria * Patients with histologically proven intracranial glioblastoma multiforme (GBM) or gliosarcoma (GS). Patients will be eligible if the original histology was low-grade glioma and…. Goal: Background: Glioblastoma is the most common and most aggressive type of malignant brain tumor. The drug pazopanib is used to treat people with a type of kidney cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: * Subjects must be \> 18 years and must voluntary sign an informed consent * Treatment-naïve patients with advanced NSCLC receiving immunotherapy alone (pembrolizumab) or combined…. Goal: This observational study explores associations between drug trough-levels and clinical outcomes in Non Small Cell Lung Cancer (NSCLC) patients treated with immunotherapy (pembrolizumab) either alone or combined with chemotherapy. Through-levels of pembrolizumab will be examined in blood samples collected during the first-line treatment period. Phase/Status/Sponsor: Unknown phase; TERMINATED; Oslo University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immunotherapy in Patient With Poor General Condition is being studied. Conditions: Non-small Cell Lung Cancer Stage IV • Eligibility: Inclusion Criteria: 1. Subjects must have signed and dated an IEC (Independent Ethic Committee) approved written informed consent form in accordance with regulatory and institutional guidelines. This must…. Goal: Immunotherapeutic approaches targeting immune checkpoint proteins PD-1/PD-L1 have recently demonstrated clinical efficacy in several cancer types, and have changed the therapeutic landscape in metastatic melanoma or non-small cell lung cancer (NSCLC). The monoclonal anti-PD-1 antibody nivolumab has been registered by both FDA (Food and Drug Administration) and EMA (European Medicine Agency), for metastatic NSCLC patients, after failure of a prior platinum-based chemotherapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Intergroupe Francophone de Cancerologie Thoracique.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) is being studied. Conditions: Lung Cancer • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of stage IV NSCLC without epidermal growth factor receptor (EGFR)-sensitizing mutation, ROS1 and/or anaplastic lymphoma kinase (ALK) translocation. * Measurable…. Goal: The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death ligand 1 (PD-L1). Phase/Status/Sponsor: Unknown phase; COMPLETED; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy is being studied. Conditions: Glioblastoma, Malignant Glioma • Eligibility: Inclusion Criteria: * Histologically confirmed newly diagnosed grade IV malignant glioma * Planned radiation treatments at Mayo Clinic Arizona or Mayo Clinic Rochester * Willing to sign release…. Goal: This phase II trial studies how well fluorodopa F 18-positron emission tomography/magnetic resonance imaging scan (18F-DOPA-PET/MRI) works in imaging elderly patients with newly diagnosed grade IV malignant glioma or glioblastoma during planning for a short course of proton beam radiation therapy. 18F-DOPA is a chemical tracer that highlights certain cells during imaging. Phase/Status/Sponsor: Unknown phase; COMPLETED; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC is being studied. Conditions: Colon Cancer • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed colorectal adenocarcinoma, with unresectable metastatic or locally advanced disease documented on diagnostic imaging studies. 2. Previously received 1-2 prior lines of…. Goal: To investigate the combination of nivolumab and ipilimumab with panitumumab in subjects with unresectable, refractory, KRAS/NRAS/BRAF wild-type, microsatellite stable (MSS) metastatic colorectal cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; UNC Lineberger Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer is being studied. Conditions: Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7 +6 • Eligibility: Inclusion Criteria: * Histological or cytological documentation of adenocarcinoma of the colon or rectum * Advanced or metastatic colorectal cancer with no curative options available and progression on…. Goal: This randomized phase II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in the body and does not respond to treatment. Regorafenib may stop the growth of colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth and by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; COMPLETED; Academic and Community Cancer Research United.

This summary may be inaccurate. Verify against ClinicalTrials.gov.